Abstract
Aim: To determine the effect of intraoperative adjunctive topical mitomycin C on intraocular pressure in patients undergoing pterygium excision.Methods: This was a descriptive interventional case series of 102 patients (118 eyes) with different grades of pterygium treated from 1995 to 2008. All patients underwent pterygium excision with intraoperative mitomycin C 0.2 mg/mL administered for 1 to 5 minutes. Changes in intraocular pressure were recorded on days 1 and 7, and at 3 months. Data were analysed using proportion, group means, standard deviations, analysis of variance, and paired Student t test.Results: There was no significant decline in intraocular pressure throughout the follow-up period (p = 0.435, Student t test). At 3 months postoperatively, 109 eyes (92.4%) had no changes in intraocular pressure >5 mm Hg, of whom 78 (72%) experienced minimal changes that were not statistically significant.Conclusions: Intraoperative topical administration of mitomycin C has a minimal effect on lowering intraocular pressure in patients with pterygium. These results do not support the trans-scleral effect of mitomycin C on the ciliary body as an intraocular pressure–lowering mechanism in glaucoma filtering surgery.
Highlights
Pterygium is one of the most common conjunctival surface disorders treated by surgical excision
Since topical mitomycin C (MMC) is extensively used as an adjunct in pterygium excision to prevent recurrence, especially in developing countries, the purpose of this study was to determine the effect on IOP in eyes affected by different grades of pterygium that were undergoing pterygium excision
This study investigated the IOP-reducing effect of intraoperative topical MMC in an Asian population with various grades of pterygia
Summary
Pterygium is one of the most common conjunctival surface disorders treated by surgical excision. One of the major limitations to simple excision is the high rate of postoperative recurrence.[1] a number of adjunctive therapies have been advocated during the past 3 decades with varying levels of success. The use of topical mitomycin C (MMC) as an adjunctive therapy to prevent pterygium recurrence has increased considerably since its introduction for pterygium by Kunitomo and Mori[2] of Japan and subsequent use in the USA by Singh et al.[3]. MMC was first developed in 1955 by Hata et al from Streptomyces caespitosus[4] and, since its inception, it has been used for treating various ocular disorders ranging from pterygium to glaucoma. Chen et al were the first researchers to use MMC intraoperatively for refractory glaucoma,[5] since it has become the drug of choice to augment trabeculectomy for effectively controlling intraocular
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
